Klingensmith Harvey Robert 4

4 · Core Laboratories Inc. /DE/ · Filed Apr 7, 2026

AI-generated summary of this filing

Updated Apr 7, 2026

Core Labs (CLB) Director Harvey Klingensmith Exercises Options & Receives Shares

What Happened

Harvey Klingensmith, a director of Core Laboratories Inc. (CLB), reported multiple transactions on April 1, 2026: an exercise/conversion of derivative instruments for 8,069 shares (reported as acquired), a grant/award of 7,895 restricted shares (acquired), and a matching disposal/transfer of 8,069 derivative shares. All transactions are reported at $0.00 consideration (total reported value $0).

Key Details

Transaction date: 2026-04-01; Form 4 filed with accession dated 2026-04-07.
Reported transactions:
- M (exercise/conversion): 8,069 shares acquired at $0.00.
- A (award/grant): 7,895 restricted shares acquired at $0.00 (derivative).
- M (exercise/conversion): 8,069 shares disposed at $0.00.
Vesting notes:
- Footnote F1: The 7,895 restricted shares will vest after a one-year period on April 1, 2027 (subject to plan terms and potential deferral).
- Footnote F2: A separate set of restricted shares vested on April 1, 2026.
Shares owned after the reported transactions: not specified in the provided filing excerpt.
Timeliness: Filing date is 2026-04-07 for transactions dated 2026-04-01. Form 4s are typically due within two business days of the transaction; check the full filing for any late-filing notation.

Context

Codes: "M" indicates exercise/conversion of a derivative (e.g., option/phantom/unit) and "A" indicates an award/grant of shares. Here, the filing shows both an acquisition via grant and conversion/exercise with a simultaneous disposal of the same 8,069 units, all at $0.00 consideration.
Interpretation for retail investors: Awards and vested restricted shares are common director compensation and do not necessarily signal a buy/sell view on the market. Purchases (cash outlay) are generally stronger bullish signals; these transactions appear to be plan-related conversions/vestings rather than open-market trades.

Form 4

Period: 2026-04-01

Director

Transactions

Exercise/Conversion
Common Stock
2026-04-01+8,069→ 50,031 total
Award
Restricted Shares
[F1]
2026-04-01+7,895→ 7,895 total
Exercise: $0.00→ Common Stock (7,895 underlying)
Exercise/Conversion
Restricted Shares
[F2]
2026-04-01−8,069→ 0 total
Exercise: $0.00→ Common Stock (8,069 underlying)

Footnotes (2)

[F1]The Restricted Shares will vest, without performance criteria, at the end of a one-year vesting period on April 1, 2027, subject to the terms of issuance. Such shares remain subject to a deferral election by the Reporting Person in accordance with Treasury Regulation 1.409A-2, and the vested portion thereof will be distributed as shares of common stock following the Reporting Person's separation of service from the Board.
[F2]The Restricted Shares vested at the end of a one-year vesting period ending April 1, 2026.

Signature

/s/ Mark Tattoli, Attorney-in-Fact|2026-04-07

1 file